ISAR is dedicated to promoting connection between scientists to advance antiviral drug discovery and development. During the COVID-19 pandemic, there is even greater need for these connections to be made rapidly and efficiently to advance important discoveries. In order to connect scientists with available resources to those with compounds or agents to assess for antiviral potency or efficacy, ISAR is establishing an open access inventory of available assays and models. If you have an assay or model that could be accessible to advance SARS-CoV-2 active agents, please use the links below. ISAR will post the list on this page and keep it updated. This list will be available not only to our Society members, but to all researchers in the global community.
If you submitted data and need to make updates, either click the edit link on your confirmation email you received when data was submitted or contact ISAR Staff at firstname.lastname@example.org.
SARS CoV-2 COVID-19 Pandemic
We publish this page in the hope that our members, and the antiviral community at large, will find it useful in their quest for a world in which viral outbreaks are no longer a constant major threat.
ISAR members are invited to submit any links that may be of interest for their evaluation and potential addition to this page.
Older information can be found in this page
Background and general information about the SARS CoV-2 and the COVID-19 outbreak:
COVID R&D: Pharmas align behind crowdsourcing solution- A partnership among pharmaceutical companies to speed up progress towards COVID-19 solutions
NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options: Health agencies and leading pharmaceutical companies to join forces to accelerate pandemic response.
A resource developed by economists providing an excellent range of statistical descriptions of the pandemic, with clear explanations of the meaning of the numbers, including their intrinsic limitations and what do they actually present.
A collection of information about pre-clinical and clinical trial stage therapeutics, drugs being used in patients, and the current regulation meetings status landscape. In response to the urgency of the COVID-19 crisis, Biocentury is making this information available for free. To visit the portal, please follow this link
A collaborative resource to develop a host-pathogens mechanism based disease map for the pathogenesis of COVID-19. To participate, or to browse through the standardized information as it is being deposited, please follow this link
Regulators split on antimalarials for COVID-19- A Discussion in The Lancet
The epidemic in Italy has remained contained in four regions in the North (Lombardia, Emilia Romagna, Veneto y Piemonte, which still have approximately 70% of all ACTIVE Italian cases). Italy is now having less than a 1,000 new cases per day.
The number of new cases has significantly decreased in Spain, from a high of almost 10,000 a day on March 26 to less than a 500 now, as has the number of deaths, from a high of almost 1,000 a day on march 31 to as low as 50 now. The outbreak has remained largely confined to Madrid and Catalunya, but Catalunya has had no new cases in the last 24 h.
Germany has had less than 500 new cases per day since May 14,
In France the number of cases has the lowest number of new cases since March 28.
The the number of daily new cases has plateau in the USA since the beginning of April and are declining now.
In the UK the total numbers of new cases and deaths has more than halved since the peaks in the first half of April.
The role of nosocomial infection in the COVID-19 outbreak in Northern Italy and the importance of community based care- NEJM Catalyst "Innovations in Care Delivery"
The Republic of Korea undertook an aggressive testing approach and has limited the number of new cases to one- to two-hundred and fifty per day in just sixteen days from the beginning, and nine days from the peak, of the outbreak
Primary sources of official information:
SARS-CoV-2 in animals, including pets- Statement from the American Veterinary Medical Association (AVMA)
All 2019-nCoV clinical trials registered and listed in "clinical trials.gov" (most are not yet recruiting)
China CDC epidemic tracking (updated daily)
Real time tracking of the epidemic by the Center for Systems Science and Engineering (CSSE), John Hopkins UniversityWHO epidemic tracking in real time
At the Epicenter of the Covid-19 Pandemic and Humanitarian Crises in Italy: Changing Perspectives on Preparation and Mitigation- NEJM Catalyst, a view from Italy about the potential major role of nosocomial transmission in the Italian outbreak
Care for Critically Ill Patients With COVID-19 JAMA insight
From Containment to Mitigation of COVID-19 in the US- JAMA viewpoint
COVID-19 Antiviral and Pharmacotherapy Recommendations- Nebraska Medicine
The Effect of the COVID-19 Pandemic on Clinic Operations -AMA Education hub
Coronavirus latest: has the outbreak in China peaked? - A commentary in Nature discussing the apparent peak and the possibility of a secondary peak around February 21 as a consequence of the return to work after the New Year Holiday
A commentary on the naming of the virus and the disease Science commentary
Covid-19: surge in cases in Italy and South Korea makes pandemic look more likely - A commentary in BMJ
Aggregated scientific information sites:
Pre-prints and Published papers:
HIGHLIGHTEDConvalescent plasma treatment of severe COVID-19: A matched control study
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis- - Large analyses of 96032 patients in 671 hospitals through the world shows increased mortality in all treatment groups including chloroquine or hydroxychloroquine
Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospital -The original preprint was posted a month ago and is under "clinical"
Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 - No benefits were observed and mortality was higher in the treated groups
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)- A Review A thorough review published in JAMA discussing the limited clinical evidence showing beneficial effects for most approaches being used
Compassionate Use of Remdesivir for Patients with Severe Covid-19- A small cohort analysis of compassionate use of remdesivir in which most patients improved, including 57% of patients under mechanical ventilation who were extubated. Mortality for patients under mechanical ventilation was only 13%, and only 1 patient not under mechanical ventilation succumbed to disease.
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potencyViral dynamics in mild and severe cases of COVID-19
COVID-19 Open Research Dataset Challenge (CORD-19) A database of publications in SARS CoV-2/COVID-19 assembled by AI
ANTIVIRAL THERAPYFavipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Of chloroquine and COVID-19 - A commentary in Antiviral Research highlighting the common failures in attempting to translate the in vitro antiviral activity of chloroquine against a number of viruses into robust in vivo antiviral activity in animal models or humans.
No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial
Two studies focusing on interactomes to identify potential drugs for repurposing (with the caveat that the safety in COVID-19 patients of drugs with known pharmacological activities is unknown):Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
MOLECULAR VIROLOGY, GENOMICS and EVOLUTION
Bat Coronaviruses in China- A pre-pandemic review discussing why it was important to study bat coronaviruses in China
Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection- an in silicons analysis predicting that dogs would be susceptible
Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS-coronavirus-2- an experimental study showing that dogs are fairly resistant to infection
Betacoronavirus Adaptation to Humans Involved Progressive Loss of Hemagglutinin-Esterase Lectin Activity -A paper from 2017 describing one potential adaptation that allowed previous betacoronaviruses to cross species barriers and infect humans
Cryo-EM structures of HKU2 and SADS-CoV spike glycoproteins and insights into coronavirus evolution- Structural analyses of the potential evolution of another coronavirus from bats to piglets
Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses -(The actual structure of the receptor binding domain has now been solved)
CLINICALEpidemiological and clinical characteristics of COVID-19 in adolescents and young adults
Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient- A small (n=3) study published in JAMA
Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019- Lymphopenia appears common
Clinical characteristics of 50404 patients with 2019-nCoV infection -A meta-analysis
Comparative study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting uncontrolled inflammation might not be the main reason of tissue injury Lymphopenia appears common
Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China-The largest description of the outbreak (>44,000 cases)
COVID-19 Antibody Seroprevalence in Santa Clara County, California - Analysis using commercial serological tests with yet not fully characterized specificity (30 negatives and 37 positives were used as controls)
SARS-like WIV1-CoV poised for human emergence -A paper from 2016 rising the prospect of a new bat coronavirus entering the human population
About ISAR NEWS
The official newsletter of the International Society for Antiviral Research
© Publications workgroup (Communications & Outreach Committee) and Luis M Schang, Editor